Eph receptors and their corresponding membrane-bound ephrin ligands regulate cell positioning and establish tissue patterns during embryonic and oncogenic development. Emerging evidence suggests that assembly of polymeric Eph signalling clusters relies on cytoskeletal reorganisation and underlies regulation by protein tyrosine phosphatases (PTPs). PTP-PEST (also known as PTPN12) is a central regulator of actin cytoskeletal dynamics. Here, we demonstrate that an N-terminal fragment of PTP-PEST, generated through an ephrinA5-triggered and spatially confined cleavage mediated by caspase-3, attenuates EphA3 receptor activation and its internalisation. Isolation of EphA3 receptor signalling clusters within intact plasma membrane fragments obtained by detergent-free cell fractionation reveals that stimulation of cells with ephrin triggers effective recruitment of this catalytically active truncated form of PTP-PEST together with key cytoskeletal and focal adhesion proteins. Importantly, modulation of actin polymerisation using pharmacological and dominant-negative approaches affects EphA3 phosphorylation in a similar manner to overexpression of PTP-PEST. We conclude that PTP-PEST regulates EphA3 activation both by affecting cytoskeletal remodelling and through its direct action as a PTP controlling EphA3 phosphorylation, indicating its multifaceted regulation of Eph signalling.
INTRODUCTION
Ephrin receptor (Eph)-ephrin signalling coordinates cell positioning by modulating cell adhesion and migration during developmental programmes such as gastrulation and vascular patterning (Nievergall et al., 2012) , but also during progression of various invasive and metastatic cancers (Boyd et al., 2014; Janes et al., 2014; Pasquale, 2010) . As a default response to ephrin contact, cell contraction and cell-cell segregation rely on intact Eph tyrosine kinase activity and ADAM10-mediated proteolytic shedding of the interacting cell surface ephrin (Hattori et al., 2000; Janes et al., 2005 Janes et al., , 2009 , initiating signalling that modulates cytoskeletal and focal adhesion proteins (Nievergall et al., 2012; Pasquale, 2008) . Emerging evidence suggests that Ephs can also be directly linked to the cortical actin cytoskeleton and to actin stress fibres (Salaita et al., 2010) , and are involved in actinmyosin polymerisation (Krupke and Burke, 2014) . However, molecular details of potential interactions between Ephs and cytoskeletal proteins, and mechanisms involved in relaying the effects of Eph clustering and transient kinase activation into a cytoskeletal reorganisation, remain largely unclear.
Previously, we have found that during ephrin-induced adhesion of leukaemia cells overexpressing EphA3, an important cancer target (Day et al., 2013; Vail et al., 2014) , PTP-PEST (also known as PTPN12), together with other focal adhesion proteins such as FAK and paxillin, is recruited into EphA3 signalling complexes (Wimmer-Kleikamp et al., 2008) . PTP-PEST is a ubiquitously expressed cytosolic protein tyrosine phosphatase that plays important roles in similar developmental processes to Ephs, including neurogenesis, vasculogenesis and mesenchymal development (Sirois et al., 2006) . It interacts with prominent focal adhesion components, such as p130Cas (also known as BCAR1) (Garton et al., 1996) and paxillin (Shen et al., 1998) , and controls cell shape and adhesion by modulating focal adhesion assembly and turnover. PTP-PEST also coordinates directed cell movement by differentially regulating Rac1 and RhoA activities through dephosphorylation of Vav2 and p190RhoGAP (also known as ARHGAP35), respectively (Angers-Loustau et al., 1999; Sastry et al., 2002 Sastry et al., , 2006 , and by controlling the subcellular localization and phosphorylation status of Rho GDP dissociation inhibitor 1 (RhoGDI1, also known as ARHGDIA) (Lee et al., 2015b) . Intriguingly, both overexpression (Garton and Tonks, 1999) and gene deletion (Angers-Loustau et al., 1999; Sastry et al., 2006) result in impaired cell motility and spreading, indicating that balanced expression levels of PTP-PEST are required for the accurate control of cell morphology and adhesion that is essential for development (Mathew et al., 2008; Taieb et al., 2008) . In addition, by directly regulating oncogenic kinases such as HER2 (also known as ERBB2) and PDGFRβ, PTP-PEST might act as a tumour suppressor in triple-negative breast cancer, where its expression is lost in more than 60% of cases (Sun et al., 2011) . Accordingly, silencing of PTP-PEST increases the phosphorylation of a multitude of proteins forming an EGFR-centred network, including Ephs and ephrinB2, and results in oncogenic transformation of mammary epithelial cells (Sun et al., 2011) .
In the case of PTPs regulating Ephs, PTP-RO (also known as PTPRU) (Shintani et al., 2006) , PTP1B (also known as PTPN1) (Nievergall et al., 2010) and PTPRF (also known as LAR) (Lee and Bennett, 2013) are known to control receptor activity, whereas SHP-2 (also known as PTPN11) and LMW-PTP (also known as ACP1) are implicated downstream of Ephs: SHP-2 is transiently recruited into EphA2 signalling complexes, dephosphorylates FAK (also known as PTK2) and contributes to loss of integrinmediated cell attachment (Miao et al., 2000) , and the presence of LMW-PTP in EphB1 and EphB2 signalling complexes affects cell adhesion (Stein et al., 1998) and is reportedly involved in modulating Rho GTPase crosstalk (Buricchi et al., 2007; Fang et al., 2008) . However, the identity and likely role of PTPs regulating the cytoskeletal remodelling that underlies Eph clustering (Salaita et al., 2010) , and Eph-induced changes to cell morphology and adhesion, remain poorly understood.
Herein, we examined the role of PTP-PEST in EphA3 function. By performing cell fractionation that allows detergent-free isolation of cell surface Eph signalling clusters, we demonstrate a corecruitment of PTP-PEST together with various focal adhesion and actin cytoskeletal proteins. We find that a caspase-3-cleaved form of PTP-PEST controls EphA3 phosphorylation, both directly and indirectly. In agreement, elevated PTP-PEST expression markedly increases EphA3 cell surface levels, inhibits EphA3 internalisation and modulates pseudopodia formation and their ephrinA5-induced retraction. Thus, PTP-PEST, by controlling cytoskeletal plasticity and by regulating EphA3 phosphorylation, plays an integral role during Eph clustering, activation and the resulting cellular response.
RESULTS

PTP-PEST is recruited to activated EphA3 and impairs its internalisation
Recruitment of PTP-PEST during EphA3-mediated adhesion of leukaemia cells to ephrinA5 surfaces (Wimmer-Kleikamp et al., 2008) , prompted us to study its role in regulating EphA3 function in adherent cells. Indeed, we found a constitutive basal interaction of endogenous PTP-PEST with EphA3, which was enhanced upon stimulation with clustered ephrinA5-Fc, also in EphA3 + AO9 melanoma cells and AO2 melanoma cells stably overexpressing EphA3 (Fig. 1A) . Time-dependent recruitment of PTP-PEST into ephrinA5-induced EphA3 signalling complexes was also evident in EphA3-stably transfected HEK293T cells (EphA3-HEK293T) (Fig. 1B) . In comparison, HEK293T cells expressing EphA3 lacking the major tyrosine phosphorylation sites (EphA3-3YF) showed reduced but residual association with PTP-PEST, confirming both constitutive and ephrin-stimulated association, which was further reduced in cells expressing EphA3 lacking the entire intracellular domain (ΔICD) (Fig. S1A) .
Confocal microscopy of co-cultures of EphA3-and GFPephrinA5-expressing HEK293T cells, which promote cell-contactdependent EphA3 activation, revealed that PTP-PEST and EphA3 colocalised at plasma membrane regions of cell-cell contact (Fig. 1C , bottom panel, filled arrows; see also Fig. S1B ). We confirmed that endogenous PTP-PEST is similarly recruited to the membrane in ephrinA5-stimulated AO2 melanoma cells expressing EphA3 (Fig. S1C) . Moreover, PTP-PEST overexpression led to the retention of clustered EphA3 at these cell contacts, whereas cells lacking exogenous PTP-PEST expression showed efficient EphA3 internalisation (Fig. 1C, top panel, open arrows) . Quantification of EphA3 cell surface levels by flow cytometry during activation with ephrinA5 (Nievergall et al., 2010) confirmed that, compared to control cells, overexpression of wild-type PTP-PEST led to significantly increased levels of EphA3 on the cell surface during the first 20 min after ephrinA5 stimulation, consistent with attenuation of ephrinA5-stimulated EphA3 endocytosis (Fig. 1D) . Interestingly, overexpression of the catalytically inactive PTP-PEST-[CS] also increased EphA3 cell surface levels, although to a lesser extent (Fig. 1D) . In contrast, PTP-PEST overexpression did not significantly affect EphA3 internalisation in cells stably expressing a kinase-inactive EphA3-[K653M] mutant (Fig. 1E ) or lacking EphA3 tyrosine phosphorylation (Janes et al., 2009) , confirming that the effects of PTP-PEST on wild-type receptor internalisation are dependent on its tyrosine phosphorylation.
PTP-PEST overexpression and inhibition of cytoskeletal remodelling attenuate EphA3 phosphorylation
Given the measurable effect of PTP-PEST on EphA3 endocytosis, we assessed whether altered PTP-PEST expression also impacts on EphA3 phosphorylation. Overexpression of wild-type PTP-PEST in EphA3-HEK293T cells significantly attenuated ephrinactivated EphA3 phosphorylation, whereas catalytically inactive PTP-PEST-[CS] significantly elevated EphA3 phosphorylation levels over a 30-min timecourse ( Fig. 2A) . PTP-PEST silencing increased the phosphotyrosine content of several proteins with an apparent molecular mass equivalent to that of EphA3 (Fig. 2B , closed arrow) and above, while at the same time decreasing the phosphorylation levels of other, apparently smaller molecular mass proteins (Fig. 2B , open arrowheads). Accordingly, anti-EphA3 antibody immunoprecipitation confirmed that PTP-PEST silencing significantly increased basal and ephrinA5-stimulated EphA3 phosphorylation (Fig. 2C ), suggesting that EphA3 is a direct substrate for PTP-PEST. In agreement with this notion, competition of direct interactions between PTPs and phosphotyrosine residues in EphA3 by addition of sodium pervanadate to cell lysates (Garton et al., 1996) significantly reduced the interaction of catalytically inactive PTP-PEST- [CS] , which acts as a trapping mutant, with EphA3 (Fig. 2D) . However, considering the crucial role of PTP-PEST in cytoskeletal remodelling, we suspected that PTP-PEST might also control EphA3 activation by regulating actin cytoskeletal changes during Eph clustering (Salaita et al., 2010) . To assess whether cytoskeletal remodelling is required for EphA3 activation, we tested pharmacological and biological inhibitors of cytoskeletal plasticity for their effect on EphA3 phosphorylation. Treatment with cytochalasin D or jasplakinolide, which inhibit or stabilise polymerisation of F-actin, respectively (Bubb et al., 2000; Cooper, 1987; Wakatsuki et al., 2001) , reduced EphA3 phosphorylation to a similar degree to that achieved by PTP-PEST overexpression (Fig. 2E) . Likewise, overexpression of the WASp homology 1 and acidic domains of the actin regulatory protein Scar1 (Scar1-WA), which has been demonstrated to inhibit actin polymerisation by sequestering Arp2/3 (Machesky and Insall, 1998) , also lowered ephrinA5-induced EphA3 phosphorylation (Fig. 2F) . Furthermore, ectopic expression of the Scar1-W domain, which unlike Scar1-WA only binds monomeric actin but not Arp2/3, attenuates EphA3 phosphorylation (Fig. 2F) . Our results show that pharmacological inhibition of actin remodelling or reduced availability of Arp2/3 or actin monomers prevent effective EphA3 activation.
PTP-PEST modulates EphA3-mediated cell retraction
To assess the involvement of PTP-PEST in EphA3-induced cytoskeletal remodelling and cell morphology changes, we studied the function of both proteins in pseudopodia formation by adopting an in vitro assay as previously described (Faux et al., 2010; Wang et al., 2010) . Confocal microscopy of EphA3-HEK293T cells cultured on microporous filters of transwell chambers revealed EphA3 on the tips of the pseudopodia (Fig. 3A, bottom) , matching the localisation of paxillin (Fig. S2) , a focal adhesion protein implicated in pseudopodia formation (Cho and Klemke, 2002; Zaidel-Bar et al., 2007) . Projections of optical z-sections through the filter confirmed the presence of EphA3 and paxillin on actin-rich pseudopodia (Fig. 3A , −ephrinA5; arrowheads), which were effectively retracted when pre-clustered ephrinA5-Fc was added to the lower chamber (Fig. 3A,B  +ephrinA5) . Quantification of the assay confirmed that, in agreement with its role in activating cytoskeletal contraction, ephrinA5-Fc caused a reproducible and highly significant reduction in EphA3-positive pseudopodia (Fig. 3C) . Overexpression of PTP-PEST caused a notable inhibition of pseudopodia formation even in non-stimulated cultures (Fig. 3B ,C, wild-type PEST), most likely due to Eph-independent effects on the cytoskeleton. However, when pseudopodia numbers were compared between samples with and without ephrin stimulation by first normalising for effects on basal pseudopodia formation, a significant inhibition of ephrininduced retraction was evident in cells expressing either wild-type or mutant PTP-PEST compared to control cells (Fig. 3D) .
We also tested retraction of filopodia-and lamellipodia-like extensions of AO9 melanoma cells expressing endogenous EphA3 plated onto chamber-slides. Whereas control cells (transfected with YFP) showed retraction of cell extensions in ∼60% of cells in response to pre-clustered ephrinA5-Fc, cells overexpressing PTP-PEST-YFP showed a markedly reduced rate of retraction (Fig. 3E) . Taken together, these data indicate PTP-PEST overexpression disrupts ephrin-Eph-dependent retraction.
Analysis of intact EphA3 plasma membrane clusters reveals the presence of various cytoskeletal components
To assess the apparent recruitment of PTP-PEST into EphA3 clusters (Fig. 1C) , as well as cytoskeletal components, we next analysed the composition of ephrin-induced EphA3 signalling complexes. For selective isolation of cell surface receptor complexes and interacting cytoskeletal proteins we adopted a fractionation approach (Fig. 4A ) that is based on detergent-free disruption of colloidal-silica-coated intact cells, followed by isolation of silica-coated cell membrane fragments by density gradient centrifugation (Chaney and Jacobson, 1983; Stolz, 1998; Stolz and Jacobson, 1992) . We modified this strategy, by using cells expressing EphA3 that is tagged with an N-terminal biotin acceptor peptide (AP N ), that allow its specific biotinylation (Howarth and Ting, 2008; Janes et al., 2009 ) and selective isolation of AP N -EphA3 receptor complexes using streptavidinconjugated magnetic beads (Fig. 4A) .
Comparison of western blots of streptavidin pulldowns from this approach and of anti-EphA3 antibody immunoprecipitates from conventional detergent-based cell lysis revealed notable differences in the profile of EphA3-associated proteins, in particular those with known involvement in focal adhesion and cytoskeletal dynamics (Fig. 4B,C) . We detected paxillin, p130Cas, CrkII (an isoform of the proto-oncogene c-Crk; also known as CRK), actin and α-actinin (Fig. 4B, left panel) , which are cytoskeletal focal adhesion proteins EphA3-HEK293T cells were cultured on transwell filter chambers facilitating extension of actin-rich pseudopodia through the 3.0 µm pores. Cells were left untreated or stimulated with pre-clustered ephrinA5-Fc as indicated. Following culture PFA-fixed and permeabilised cells were analysed with primary and Alexa-Fluor-conjugated secondary antibodies against actin (A, green), EphA3 (E, red) and paxillin (P, white). Nuclei demarking the cell body were stained with Hoechst 33342 (H, blue). Merged images revealing indicated antibody combinations are shown. Maximum projections of optical (z-) sections through the cell body (top panel) and pseudopodia (bottom panel) are illustrated together with z-projections of front views of cell bodies and pseudopodia reaching to the underside of the membrane. Boxed areas are shown at a two-fold increased magnification as indicated. Arrowheads indicate pseudopodia co-stained with EphA3 and actin and paxillin. (B) EphA3-HEK293T cells were seeded into transwell filter chambers prior to transfection with eGFP (ctrl) or Myc-tagged wild-type (w/t) or [CS] PTP-PEST-YFP. After 24 h, pre-clustered ephrinA5 was added to the lower chamber (40 min) as indicated. Prior to staining, cells at the top or bottom of parallel filters were removed to allow selective imaging of cell bodies (top) and cellular protrusions (bottom), respectively. Insets show zoomed co-staining of EphA3 and PEST (anti-Myc antibody) in pseudopodia. (C) The number of pseudopodia was quantified from lower magnification images of EphA3-associated fluorescence, each representing five fields of view, using the particle count analysis in ImageJ. Ten images per condition were analysed. (D) The data in C were normalised to basal conditions for each transfected culture to assess only effects on the Eph-ephrin-dependent response. *P<0.05; **P<0.01 (two-tailed t-test). (E) AO9 melanoma cells endogenously expressing EphA3 were plated onto chamber slides and transfected with YFP-tagged PTP-PEST or YFP only as control. Cells were analysed the next day by wide-field fluorescence microscopy, before and 20 min after stimulation with cross-linked ephrinA5-Fc. Graph shows quantification of the proportion of cells (%) showing retraction of cellular extensions (mean±s.e.m. from an average of ∼40 cells per treatment, n=3 experiments) ***P<0.001 (two-tailed t-test). Arrows indicate areas of retraction. Dimension bars show length of cell protrusions, and dotted lines highlight extent of retraction. Scale bars are in μm.
that were not present in the corresponding membrane fraction of the cytoplasmic-truncated EphA3[ΔCPD], indicating their specific recruitment into signalling-competent EphA3 clusters (Fig. 4B , right panel). The specificity of the plasma membrane isolation was confirmed by the preferential fractionation of lysosomal (LAMP-1) and plasma membrane (VLA2; α2β1 integrin) marker proteins into cytosolic and plasma membrane compartments, respectively (Fig. 4B) . Interestingly, FAK was constitutively associated with both isolated EphA3 and EphA3[ΔCPD] clusters (Fig. 4B) , suggesting that FAK recruitment to the EphA3 signalling complex does not occur through direct binding to the EphA3 intracellular domain. Immunoprecipitates from whole-cell detergent lysates also revealed the constitutive presence of FAK (Fig. 4C ), but not of other focal adhesion proteins, whose association might have been lost during detergent lysis and sedimentation of the detergent-insoluble fraction prior to immunoprecipitation. This comparison emphasises the value of using our modified technique for detergent-free cell membrane isolation for analysis of cytoskeletal-protein-membranereceptor complexes.
An N-terminal fragment of PTP-PEST preferentially localises to EphA3 at the plasma membrane
We next exploited this detergent-free cell fractionation strategy to examine the recruitment of PTP-PEST to EphA3 signalling clusters. Western blotting for endogenous PTP-PEST showed it was indeed recruited into EphA3 signalling clusters (Fig. 5A) . In addition to the full-length protein of ∼100 kDa, smaller molecular mass bands were also detected with an anti-PTP-PEST antibody (AG10) recognising the N-terminus, suggesting the presence of the cleaved PTP-PEST forms previously identified (Halle et al., 2007) . To investigate this further, we transfected cells with a PTP-PEST construct (Fig. 5B ), tagged at its N-and C-termini with Myc-CFP, and YFP, respectively (Halle et al., 2007) . Again we found that, in addition to full length PTP-PEST, N-terminal Myc- PTP-PEST fragments were preferentially detected in active EphA3 plasma membrane clusters. In this case, the full-length protein was more evenly distributed across the cytosol, plasma membrane and EphA3-enriched plasma membrane fractions of ephrinA5-stimulated cells, probably due to its overexpression (Fig. 5C ). Western blotting with anti-GFP antibodies (recognising YFP and CFP) showed the same cleaved bands, but no additional smaller bands representing the C-terminus, indicating presence only of N-terminal PTP-PEST fragments (Fig. S3) .
Caspase-3 has been shown to cleave PTP-PEST, generating an N-terminal fragment with elevated enzymatic activity and altered scaffolding properties (Halle et al., 2007) . In agreement, we found that treatment with the pan-specific caspase inhibitor Z-VAD-fmk markedly reduced the presence of truncated Myc-PTP-PEST in the EphA3-enriched plasma membrane fraction (Fig. 5C ). In addition, analysis of anti-EphA3 phosphotyrosine blots showed that caspase inhibition notably reversed the attenuation of EphA3 phosphorylation that was observed upon PTP-PEST overexpression (Fig. 5D,E) . We also found that cells expressing PTP-PEST mutated at the previously identified caspase cleavage site 549 DSPD (Halle et al., 2007 ) displayed a similarly higher ephrin-induced EphA3 phosphorylation in comparison to wild-type PTP-PEST (Fig. S4A,B) . In addition to cleavage of PTP-PEST, probing of plasma membrane clusters for p130Cas revealed a distinct ∼60-kDa protein fragment (Fig. S4C) , suggesting that caspase-3-mediated cleavage of p130Cas occurs in parallel to cleavage of PTP-PEST, as found previously (Halle et al., 2007) .
We next thought to assess whether accumulation of truncated Myc-PTP-PEST could be detected in EphA3 cell surface clusters in intact cells by microscopic analysis to confirm the cell fractionation experiments. Transfection of EphA3-positive AO2 melanoma cells with the Myc-PTP-PEST-YFP construct with distinct N-and C-terminal tags allowed us to distinguish the non-cleaved fusion protein with YFP-(and anti-Myc)-associated fluorescence, from the N-terminal PTP-PEST fragment carrying solely anti-Mycassociated fluorescence. We found that stimulation of EphA3 with ephrinA5-Fc lead to more pronounced accumulation of the N-terminal Myc-PTP-PEST fragment into distinct clusters at the cell periphery compared to YFP fluorescence, which remained more uniformly distributed between the cell membrane and cytosol (Fig. 6A,B) .
Taken together, these experiments suggest that a caspase-3-cleaved N-terminal PTP-PEST fragment is selectively accumulated in EphA3 signalling clusters and controls the activation of EphA3 at the plasma membrane.
EphrinA5 stimulation induces caspase-3 cleavage
To elucidate whether this accumulation of truncated PTP-PEST in response to EphA3 activation is due to preferential recruitment of the N-terminal PTP-PEST fragment into EphA3 signalling clusters, or due to increased cleavage and activation of pro-caspase-3 at the plasma membrane, we examined potential changes in caspase-3 activity during ephrin stimulation. Indeed, caspase-3 activity significantly increased after treatment of EphA3-HEK293T cells with pre-clustered ephrinA5 (Fig. 7A) , reaching a maximum after 10 min, whereas cells expressing the kinase-inactive (Halle et al., 2007) illustrating the catalytic domain (PTP), the five proline-rich regions (P1, P2, P3, P4 and CTH) and the Shc-binding domain (NPLH). The N-terminus continues into a Myc-CFP tag, the C-terminus of PTP-PEST forms a fusion with YFP. (C) EphA3-HEK293T cells transfected with a control vector or Myc-PTP-PEST-YFP and exposed to DMSO or Z-VAD-fmk (50 μM) for 6 h were stimulated (15 min) with ephrinA5-Fc or left untreated. EphA3 and PTP-PEST (full-length and truncated) levels were analysed in cytosolic, EphA3-PM and total plasma membrane (PM) fractions obtained by colloidal-silicafacilitated plasma membrane isolation, using western blotting with anti-EphA3 and anti-Myc antibodies. (D) Attenuation of EphA3 phosphorylation by PTP-PEST is reversed by caspase inhibition. EphA3-HEK293T cells were transfected with control vector or Myc-PTP-PEST-YFP, and incubated with Z-VAD-fmk (50 μM) or DMSO for 6 h, and with ephrinA5-Fc as indicated. AntiEphA3 immunoprecipitates and detergent lysates were immunoblotted with antibodies against phosphotyrosine residues (PY), EphA3 and Myc. (E) EphA3 phosphorylation levels normalised to total EphA3 were estimated by densitometry from experiments as in D; mean±s.d. are shown (n=3). ***P<0.001 (two-tailed t-test). (Fig. 7B) , revealed a much less prominent rise in caspase-3 activity with residual activity likely due to endogenous wild-type EphA receptor expression (Dottori et al., 1999;  Fig. S1A ). This suggests that EphA3 activation triggers caspase-3 activation and PTP-PEST cleavage that is localised within EphA3 signalling clusters. In agreement, we find pro-caspase-3 present in anti-EphA3 immunoprecipitations (Fig. 7C ) and in streptavidin pulldowns (Fig. 7D ) of cell surface EphA3. Stimulation with pre-clustered ephrinA5-Fc markedly increased the association and the appearance of cleaved active caspase-3 in EphA3 complexes (Fig. 7C,D) , but not in the remainder of the cell membrane or cytosolic compartments (Fig. 7D) . Such a spatially confined caspase-3-cleavage of PTP-PEST would explain the lack of an obvious increase of truncated PTP-PEST in whole-cell lysates (Fig. 5D) . It also explains, in agreement with previous findings (Lawrenson et al., 2002 ), why we did not detect any evidence for increased apoptosis during or after ephrinA5 stimulation (data not shown), suggesting a non-apoptotic role for the transient and highly localised caspase-3 activation in response to EphA3 activation.
EphA3-[K653M]
DISCUSSION
Active Eph kinase signalling, required for the segregation between Eph-and ephrin-expressing cells (Holmberg and Frisen, 2002; Nievergall et al., 2012) , is controlled by Eph-associated PTPs acting at the cell surface and during endocytosis of Eph-ephrin signalling complexes. Additional PTPs, including SHP-2 and LMW-PTP, act as crucial regulators of cell signalling downstream of activated Ephs (Miao et al., 2000; Stein et al., 1998) . Here, we demonstrate that PTP-PEST, a tyrosine phosphatase and scaffolding protein with crucial functions in the assembly and disassembly of the actin cytoskeleton during cell movement (Angers-Loustau et al., 1999; Garton and Tonks, 1999; Sastry et al., 2002 Sastry et al., , 2006 ) and cell-cell adhesion (Espejo et al., 2010) , is involved in regulating cell-morphological responses during EphA3 signalling, and controls EphA3 tyrosine phosphorylation levels directly. Considering that Eph clustering and activation relies on dynamic reorganisation of actin fibres (Salaita et al., 2010) , PTP-PEST might influence the efficacy of Eph clustering and kinase activation by controlling cytoskeletal remodelling. Confirming the crucial role of cytoskeletal plasticity for EphA3 activation, we demonstrate that, similar to deregulated PTP-PEST expression, pharmacological or dominant-negative protein inhibition of cytoskeletal remodelling notably attenuates EphA3 phosphorylation.
Interestingly, our novel analysis of EphA3 cell surface clusters also revealed that a caspase-3-generated, catalytically active Nterminal form of PTP-PEST is preferentially present in EphA3 signalling complexes, and controls EphA3 phosphorylation and activity in a spatially confined manner. Based on these observations, we suggest a new model for PTP-PEST involvement in EphA3 activity and the Eph-ephrin-dependent cellular response (Fig. 8) , as discussed further below.
Regulation of EphA3 activity by PTP-PEST
We reported previously that the prototypic ER-resident tyrosine phosphatase PTP1B regulates EphA3 tyrosine kinase signalling, controlling primarily ephrin-induced EphA3 phosphorylation and endocytosis rather than basal phosphorylation (Nievergall et al., 2010) , and suggested that another PTP might be involved in EphA3 signalling. Indeed, we now demonstrate that PTP-PEST, which is constitutively associated with EphA3 at the cell surface, controls the tyrosine phosphorylation and signalling functions of EphA3. Thus, exogenous PTP-PEST expression significantly reduced basal and ephrin-induced EphA3 phosphorylation, whereas small interfering RNA (siRNA)-mediated silencing, or ectopic expression of the inactive [CS]-trapping mutant, elevated EphA3 phosphorylation.
PTP-PEST also directly regulates other receptor tyrosine kinases (RTKs). It has been shown to directly interact with EGFR and HER2 receptors and control their signalling, a function which is lost due to its mutation in some triple-negative breast cancers (TNBC) (Sun et al., 2011) . Importantly, in mammary epithelial cells, silencing of PTP-PEST leads to hyper-phosphorylation of not only EGFR and HER2, but also EphA2 and EphB4, among other RTKs (Sun et al., 2011) , supporting our finding that Ephs serve as a direct PTP-PEST substrate. In agreement, TNBC clinical samples are enriched in the phosphorylated forms of several RTKs, including EphA2 and EphA3 (Albeck and Brugge, 2011) , indicating that the tumour suppressor function of PTP-PEST might be conferred by a range of relatively minor changes to its interaction with substrate proteins (Albeck and Brugge, 2011; Sun et al., 2011) , including Ephs. 
A caspase-cleaved PTP-PEST N-terminal PTP fragment controls EphA3 signalling
Intriguingly we found that a C-terminally truncated PTP-PEST fragment, recruited together with full-length PTP-PEST, preferentially accumulated within (active) EphA3-enriched plasma membrane patches. We showed that caspase inhibition prevented PTP-PEST cleavage and PTP-PEST-mediated EphA3 de-phosphorylation, whereas ephrin-stimulation increased caspase-3 activity within EphA3 signalling clusters. These results suggest that a caspase-3-cleaved PTP-PEST fragment generated during EphA3 clustering controls EphA3-phosphorylationinduced cytoskeletal remodelling. Similarly, a caspase-3-cleaved N-terminal PTP-PEST fragment with enhanced phosphatase activity has been described previously, and this fragment retained the ability to interact with paxillin but no longer bound to Shc, Csk and PSTPIP1 (Halle et al., 2007 ). In our current study, we detect a ∼75-kDa PTP-PEST fragment in addition to the ∼110-kDa fragment described previously and shown to be generated by cleavage of 549 DSPD, one of the three 'DXXD' caspase 3 consensus cleavage sites (Halle et al., 2007) , suggesting that further proteolysis occurs. Mutation of the 549 DSPD cleavage site inhibited ephrin-activated PTP-PEST cleavage, reducing the appearance of both the 110-kDa and 75-kDa bands, and increasing EphA3 phosphorylation. , respectively, were stimulated with pre-clustered ephrinA5-Fc as indicated or treated with 1 μM staurosporin for 1 h ( positive control). Caspase-3 activity was determined by measuring the cleavage of a fluorescent substrate as described in Materials and Methods. Results are mean±s.e.m. of three independent experiments. ***P<0.001 (two-tailed t-test). (B) Anti-EphA3 immunoprecipitates from detergent lysates of untreated or ephrinA5-stimulated wild-type EphA3 (w/t) and EphA3-[K653M] expressing HEK293T cells were immunoblotted for EphA3 and phosphotyrosine-EphA3 ( pY-EphA3) levels as indicated to verify kinase inactivity. (C) Caspase-3 recruitment and cleavage was examined by western blotting of anti-EphA3 immunoprecipitations of untreated or ephrinA5-stimulated EphA3-HEK293T cell lysates. (D) HEK293T stably expressing biotinylated EphA3 were stimulated with ephrinA5-Fc followed by incubation with streptavidin-conjugated Dynabeads and the separation of cytosolic EphA3-enriched plasma membrane (EphA3-PM) and total plasma membrane (PM) fractions as shown in Fig. S3 . Caspase-3 cleavage (activation) and EphA3 protein levels were determined by western blotting using anti-caspase-3 and anti-EphA3 antibodies, respectively. Fig. 8 . Model for PTP-PEST involvement in EphA3 activity and cellular response. A novel method for isolation of EphA3 signalling clusters revealed that they were associated with multiple proteins associated with the actin cytoskeleton, including PTP-PEST, a known regulator of many of these proteins, and with cytoskeletal remodelling (black T-bars). We propose that PTP-PEST regulates both basal EphA3 tyrosine phosphorylation and ephrinstimulated EphA3 activity, internalisation and Ephephrin-mediated retraction in multiple ways (red T-bars. First, it does so indirectly, through its effects on cytoskeletal remodelling, supported by effects of direct inhibitors of actin polymerisation and depolymerisation, which inhibit EphA3 activation; and, second, it does so directly, whereby EphA3 clustering and activation promotes caspasemediated cleavage of PTP-PEST, resulting in an N-terminal fragment that is preferentially found in active EphA3 clusters. In support, inhibition of caspase activity inhibits effects of PTP-PEST on EphA3 phosphorylation.
In support of our findings, other studies confirm interaction of EphA receptors with caspases, including the upstream activator caspase 8 with EphA7, thought to be mediated by an unidentified intermediate transmembrane protein (Lee et al., 2015a) . Caspase 3 activation has also been found to coincide with ephrin-induced EphA4 activation, albeit in an apoptotic situation (Park et al., 2013) . Although Eph activation-induced apoptosis might play a role during neural development (Depaepe et al., 2005; Duffy et al., 2008) , we have demonstrated previously that in EphA3-HEK293 and melanoma cells ephrinA5-induced cell contraction does not induce apoptosis (Lawrenson et al., 2002) , indicating that localised caspase-3 activation and PTP-PEST cleavage in ephrin-stimulated EphA3-HEK293 cells reflects one of the non-apoptotic caspase functions that have been previously described (Miura, 2012) .
PTP-PEST and EphA3-controlled cell protrusion and retraction
Both PTP-PEST and Eph receptors are known to be instrumental for the cytoskeletal remodelling that underlies the capacity for dynamic cell shape and morphology changes (Angers-Loustau et al., 1999; Garton and Tonks, 1999; Nievergall et al., 2012; Pasquale, 2008) . Thus, in order to assess a potential interdependence of PTP-PEST and Eph function, we adopted pseudopodium formation as an in vitro model (Cho and Klemke, 2002; Wang et al., 2007 Wang et al., , 2010 . In agreement with studies identifying EphA2 as being among the proteins most highly enriched and phosphorylated in COS7 cell pseudopodia (Wang et al., 2007) , we found EphA3 localising to EphA3-HEK293 cell pseudopodia together with paxillin, a cytoskeletal adaptor implicated in pseudopodia extension and retraction (Cho and Klemke, 2002; Zaidel-Bar et al., 2007) . Stimulation of the cells with ephrinA5 triggered effective pseudopodia retraction, and PTP-PEST overexpression reduced both the extension of EphA3-rich pseudopodia and their retraction in response to ephrinA5, suggesting that it is involved in EphA3-induced cytoskeletal reorganisation. This is supported by similar inhibition of ephrin-induced retraction of filopodia-and lamellipodia-like extensions in AO9 melanoma cells expressing endogenous EphA3. Cytoskeletal retraction requires disassembly of the p130Cas-Crk complex and Rac1 downregulation (Cho and Klemke, 2002) , processes modulated by both Eph receptors (Lawrenson et al., 2002; Wahl et al., 2000) and PTP-PEST (Garton et al., 1996; Sastry et al., 2002) . Thus, inhibition of retraction by PTP-PEST likely involves both direct effects on Eph receptor activity as well as effects on cytoskeletal remodelling downstream of activated EphA3.
Recruitment of cytoskeletal and focal adhesion components into EphA3 plasma membrane clusters
Our study of signalling clusters from detergent-free fractionation confirms an emerging notion that Eph receptors might have direct links to the cortical actin cytoskeleton (Salaita et al., 2010) . Our analysis of EphA3 cell surface signalling clusters reveals that important focal adhesion proteins, including paxillin, p130Cas, CrkII and α-actinin, are associated with EphA3 in addition to the previously identified PTP-PEST and FAK (Miao et al., 2000; Wimmer-Kleikamp et al., 2008) . Importantly, our new approach reveals that actin and its linker protein α-actinin are specifically recruited into cell surface clusters of active EphA3, suggesting that it functions (with the other focal adhesion proteins) in facilitating cytoskeletal reorganisation during Eph clustering. Indeed, cytoskeletal remodelling is not only a consequence of Eph activation, where rapid actin depolymerisation causes cytoskeletal collapse (Carter et al., 2002; Meima et al., 1997) , but is also required during ephrinA1-induced EphA2 signalling cluster assembly and activation (Salaita et al., 2010) . α-actinin primarily acts in focal adhesions to connect β-integrins to filamentous actin, but in agreement with its central role in focal adhesion signalling also binds several other proteins, including FAK (Izaguirre et al., 2001) , vinculin and zyxin (Otey and Carpen, 2004; VicenteManzanares et al., 2009) . Taken together, our data indicate that α-actinin might provide a physical link between EphA3 and the actin cytoskeleton, acting to facilitate the rapid remodelling that must occur during Eph clustering.
There is precedence for cytoskeletal regulation of RTK signalling, including an EGFR response (Chung et al., 2010) , likely involving the cortical actin cytoskeleton compartmentalising the plasma membrane, confining lateral movement of transmembrane proteins and impacting on receptor oligomerisation and cellular signalling (Grecco et al., 2011; Kusumi et al., 2005; Morone et al., 2006) . Thus, our finding that inhibition of actin cytoskeletal dynamics reduced EphA3 phosphorylation similarly to PTP-PEST overexpression might suggest that PTP-PEST function also facilitates synchronised cytoskeletal remodelling during the assembly of EphA3 signalling clusters. In agreement, combined ectopic PTP-PEST expression and cytochalasin D treatment did not reduce EphA3 phosphorylation further than that achieved with single treatments (data not shown).
In summary, our data conclusively establish a crucial role for PTP-PEST in EphA3 receptor activation and Eph-induced cytoskeletal plasticity. Localised caspase-mediated cleavage generates an Nterminal PTP-PEST fragment within EphA3 plasma membrane clusters that controls EphA3 phosphorylation and endocytosis and likely also facilitates the destabilisation of the actin network necessary for cell rounding and migration. The modulation of integrin-mediated adhesion and cytoskeletal remodelling has been extensively studied in Eph-ephrin signalling (Nievergall et al., 2012) ; however, the notion that efficient Eph receptor activation might rely on positive feedback from adhesion signalling pathways is only starting to be recognised, as exemplified by a study reporting that integrin-mediated adhesion potentiates ligand-stimulated EphB4 phosphorylation in breast cancer cells (Noren et al., 2009) . In light of the documented importance of both Eph-ephrin-and PTP-PEST signalling during tumour promotion and invasion, the control of Ephinduced cytoskeletal signalling by PTP-PEST will likely play an important role for the motility of cancer cells.
MATERIALS AND METHODS
Expression constructs
Mammalian pEFBos or pcDNA4 expression vectors with full-length EphA3 and EphA3 tagged with N-terminal biotin acceptor peptide (AP N ) have been described previously (Janes et al., 2009; Lawrenson et al., 2002) . For the generation of EphA3-expressing PTP-PEST reconstituted PTP-PEST −/− MEFs, AP N -EphA3 was subcloned into pcDNA3.1-hygro. The AP NEphA3[ΔCPD] cytoplasmic deletion construct was produced by introducing a stop codon at Y570 of EphA3 using site-directed mutagenesis (QuikChange XL, Stratagene). The pCS2mycECFP-PTP-PEST-EYFP construct (expressing either wild-type or the inactive C231S mutant) was as described previously (Halle et al., 2007) . Scar1-WA and Scar1-W constructs in pRK5-Myc were a kind gift of Klemens Rottner (University of Bonn, Germany) and are described elsewhere (Machesky and Insall, 1998) .
Reagents and antibodies
Production and purification of an ectodomain-Fc-fusion protein of ephrinA5 and the native EphA3-specific monoclonal antibody (clone IIIA4) have been described previously (Lawrenson et al., 2002) . Antigen-affinitypurified sheep and rabbit polyclonal antibodies raised against the soluble EphA3 extracellular domain were used for immunoblots and immunofluorescence, respectively. A rabbit polyclonal antibody against PTP-PEST was kindly supplied by Nick Tonks (Cold Spring Harbor Laboratory, USA) and clone AG10 (Cell Signaling) were used for PTP-PEST western blots, whereas a monoclonal antibody (clone AG26, Chemicon) was employed in immunofluorescence applications. Other antibodies were from Millipore (anti-phosphotyrosine monoclonal antibody 4G10), Abcam (the antibody recognising phosphorylated EphA2, EphA3 and EphA4), NeoMarkers (anti-actin monoclonal antibody, clone ACTN05), BD Biosciences (anti-paxillin monoclonal antibody, clone 349), Upstate (anti-Myc monoclonal antibody clone 9E10, rabbit anti-FAK polyclonal antibody) and Cell Signaling (anti-caspase-3 antibody, clone 8G10). Horseradish peroxidase (HRP)-labelled secondary antibodies and anti-human-Fc antibody were from Jackson laboratories, except HRPconjugated anti-rabbit-IgG antibody, which was from Bio-Rad. Primary antibodies were used at a dilution of 1:1000, and secondary antibodies were used at a dilution of 1:5000. For immunofluorescence studies, mouse antiMyc tag monoclonal antibody directly conjugated to A647 (clone 9B11) was obtained from Cell Signaling Technology. Alexa-Fluor-labelled secondary antibodies and phalloidin were purchased from Molecular Probes. Monovalent streptavidin ( provided by Alice Ting, Massachusetts Institute of Technology, USA) was labelled with Alexa Fluor 594 dye (Molecular Probes) following the manufacturer's protocol. Jasplakinolide was from Calbiochem and cytochalasin D and Z-VAD-fmk from Sigma.
Cell culture
Human kidney epithelial 293T (HEK293T) and COS7 cells (both from the ATCC) were maintained in Dulbecco's modified Eagle's medium (DMEM), 10% fetal calf serum (FCS) and 2 mM L-Glutamine in a 5% CO 2 and 95% air atmosphere. Stable cell clones expressing EphA3 (EphA3-HEK293T) and ephrinA5-GFP (ephrinA5-HEK293T) (Janes et al., 2005) were kept in DMEM, 10% FCS containing 2 µg/ml puromycin and 400 µg/ml G418, respectively. Stable HEK293T cells expressing AP N -EphA3[ΔCPD] and the transmembrane form of the biotin ligase BirA (TM-BirA) were generated through sequential clonal selection (0.2 mg/ml zeocin, 400 µg/ml G418) as previously described for AP NEphA3/TM-BirA HEK293T cells (Nievergall et al., 2010) . Mouse embryonic fibroblasts (MEFs) from PTP-PEST-deficient mouse embryos (Cote et al., 2002) and the corresponding wild-type-PTP-PEST reconstituted cell line (clone B118) (Halle et al., 2007) were cultured in DMEM containing 10% FCS, with the addition of 50 µg/ml zeocin for the latter. AP N -EphA3 overexpressing PTP-deficient and reconstituted MEFs were generated by clonal selection (0.1 mg/ml hygromycin). Transfections of cDNA or siRNA were performed with Lipofectamine 2000 (Invitrogen) following the manufacturer's instructions. HP Validated siRNA (SI02658761, Qiagen) at 20-40 nM, transfected 72 h prior to analysis, was used to facilitate PTP-PEST silencing. AO9 melanoma cells (Lawrenson et al., 2002) and EphA3-overexpressing AO2 melanoma cells (Vearing et al., 2005) have been described previously. All cell lines are routinely tested for contamination.
Ephrin stimulation, immunoprecipitation and western blotting
For ligand stimulation, ephrinA5-Fc (1.5 µg/ml) was pre-clustered using goat anti-human-IgG antibody (Fcγ-specific) and applied to the cells for 10 min or as indicated. Whole-cell lysis was performed in 50 mM Tris-HCl pH 7.4, 150 mM NaCl, 1% Triton X-100, 0.1% SDS, 1 mM NaVO 4 , 10 mM NaF and protease inhibitors (cOmplete, Roche). EphA3 was immunoprecipitated from cell lysates with monoclonal antibody IIIA4 conjugated to divinyl-sulfone-activated Mini-Leak beads (KemEnTec) as previously described (Janes et al., 2005) . Immunoprecipitates or whole-cell lysates were analysed by western blotting with appropriate antibodies, and blots were visualised using an ECL substrate (Supersignal, ThermoFisher Scientific).
Preparation of the EphA3-containing plasma membrane fraction
We modified a colloidal silica membrane isolation approach originally established by Chaney and Jacobson (1983) and refined by Stolz et al. (Stolz, 1998; Stolz and Jacobson, 1992) to isolate an intact EphA3-plasma membrane fraction (see Fig. S1 ). HEK293T cells expressing AP N -EphA3 and TM-BirA (1×10 8 - 2×10 8 ) were stimulated with pre-clustered ephrinA5 for 10 min in suspension or left untreated, and subsequently incubated with 60 μl streptavidin Dynabeads (MyOne C1, Invitrogen) for 5 min. After washing with 10 ml cold PBS, cells were resuspended in 4 ml of plasma membrane coating buffer (PMCB; 20 mM MES, 150 mM NaCl, 280 mM sorbitol, pH 5.5; cold). The cell suspension was slowly added dropwise into 4 ml of a 1% cationic colloidal silica suspension (Alcoa World Chemicals, prepared in PMCB from a 30% stock solution) using a syringe and needle while gently vortexing and thereafter immediately diluted with PMCB to 45 ml. The silica-coated cells were sedimented at 900 g for 2 min at 4°C and washed twice with 45 ml PMCB to remove any excess silica. The cells resuspended in 1 ml of PMCB were added dropwise into 5 ml of 1 mg/ml polyacrylic acid solution (PAA, Sigma) in PMCB, pH 6-6.5, using a syringe and needle while gently vortexing prior to immediate dilution with PMCB to 45 ml. The silica-and PAA-coated cells were sedimented at 900 g for 2 min at 4°C and washed three times with 45 ml PMCB to remove any excess PAA. Next, cells were incubated for 10 min on ice with 10 ml hypotonic lysis buffer containing 20 mM Tris-HCl, pH 7.5, 5 mM sodium pyrophosphate, 1 mM NaVO 4 , 10 mM NaF and protease inhibitors (cOmplete, Roche). Nitrogen cavitation at 30 bar for 15 min in a Parr bomb (model 4635, Parr Instrument Company) was used to disrupt the cells. The disrupted cells were layered onto a 3 ml cushion of 60% Optiprep medium (Axis-Shield, Norway; adjusted with 2 M Tris-HCl, pH 7.5, to 20 mM Tris) and fractionated for 20 min at 28,000 g. The silica-coated plasma membranes containing streptavidin-Dynabead-bound EphA3 clusters sediment into the bottom fraction while nuclei together with nonbound streptavidin beads are found on top of the Optiprep cushion below the supernatant containing the cytosolic fraction. After resuspending the pellet in 1 ml of 20 mM Tris-HCl pH 7.5, 150 mM NaCl, 1% Triton X-100 and protease inhibitors (cOmplete, Roche), EphA3 signalling clusters were isolated using a magnet (Dynal, Invitrogen).
Internalisation assay
HEK293T cells stably expressing AP N -EphA3 and TM-BirA (i.e. biotinylated EphA3), growing in triplicate wells in 96-well plates and transfected with PTP-PEST or control constructs as indicated were serumstarved, treated with pre-clustered ephrinA5-Fc for 20 min and labelled with Alexa-Fluor-594-tagged monovalent streptavidin in FACS buffer (1% FCS, 0.5 mM EDTA in PBS) for 30 min at 4°C. Flow cytometry was performed on an LSRII (BectonDickinson) and raw data analysed using FlowJo (Tree Star, Inc.).
Caspase-3 activity assay
Assays to determine caspase-3 enzymatic activity were performed using the ApoAlert caspase-3 fluorescent assay kit (BD Biosciences) according to the manufacturer's instruction. Briefly, 10 6 HEK293T cells expressing either wild-type EphA3 or kinase-dead EphA3-[K653M] were seeded in 60-mm dishes. After 24 h of serum starvation (1% FCS in DMEM), cells were stimulated with ephrinA5 for the indicated times or treated with 1 μM staurosporin for 1 h at 37°C. Cell lysates were incubated with 50 µM caspase-3 substrate (DEVD-AFC) for 1 h at 37°C. The cleavage product of this substrate was detected using the FLUOstar OPTIMA plate reader (BMG Labtech) equipped with 400-nm excitation and 505-nm emission filters.
membrane that was coated with fibronectin prior to seeding. To initiate pseudopodia retraction, pre-clustered ephrinA5-Fc was placed in the lower chamber for 40 min, whereas controls were left untreated. Cells were then fixed with PFA and permeabilised as above. Cells were stained with antibodies and phalloidin as indicated, and membranes were mounted in Mowiol to permit analysis by confocal microscopy. The number of pseudopodia was estimated by counting particles in random fields of view using ImageJ.
AO9 retraction assay
AO9 melanoma cells were plated sparsely onto eight-well chamber coverslips (Ibidi) and tranfected with wild-type PTP-PEST-YFP or YFP as control. After 24 h, cells were analysed by wide-field fluorescence microscopy (Leica AF6000LX) using the 'mark and find' function, before and 20 min after stimulation with ephrinA5-Fc, pre-cross-linked as described above. An average of ∼40 cells per treatment were analysed in n=3 experiments.
Statistical analysis
Graphpad Prism and Excel software were used for graphs and statistical analysis. Data are presented as mean±s.e.m. Two-tailed t-tests were used to compare two variables and two-way ANOVA for multiple parameters.
